S117: CHEMOTHERAPY-FREE TREATMENT WITH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB FOR OLDER ADULTS WITH NEWLY-DIAGNOSED, PH-NEGATIVE, CD22-POSITIVE, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: ALLIANCE A041703

• Matthew Wieduwilt,
• Jun Yin,
• Oudom Kour,
• Rebecca Teske,
• Wendy Stock,
• Ken Byrd,
• Kimberly Doucette,
• James Mangan,
• Gregory Masters,
• Alice Mims,
• Katarzyna Jamieson,
• Shira Dinner,
• Ali Bseiso,
• Geoffrey Uy,
• Harry Erba,
• Mark Litzow,
• Richard Stone

Affiliations

Matthew Wieduwilt

1 Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

Jun Yin

2 Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota, United States

Oudom Kour

2 Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota, United States

Rebecca Teske

2 Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota, United States

Wendy Stock

3 University of Chicago, Chicago, Illinois, United States

Ken Byrd

4 University of Kansas, Kansas City, Missouri, United States

Kimberly Doucette

5 MedStar Georgetown University Hospital, Washington DC, United States

James Mangan

6 University of California San Diego, La Jolla, California, United States

Gregory Masters

7 Christiana Care Health System, Newark, Delaware, United States

Alice Mims

8 The Ohio State University Medical Center, Columbus, Ohio, United States

Katarzyna Jamieson

9 University of North Carolina, Chapel Hill, North Carolina, United States

Shira Dinner

10 Northwestern University, Chicago, Illinois, United States

Ali Bseiso

11 University Hospitals, Cleveland, Ohio, United States

Geoffrey Uy

12 University of Washington, St. Louis, Missouri, United States

Harry Erba

13 Duke University, Durhmam, North Carolina, United States

Mark Litzow

14 Mayo Clinic, Rochester, Minnesota, United States

Richard Stone

15 Dana-Farber Cancer Institute, Boston, Massachusetts, United States